The treatment of intra-and extrahepatic cholangiocarcinomas remains a medical challenge. Due to the poor efficacy of conventional chemotherapy, surgical treatment modalities represent the only chance of attaining long-term survival and cure. The introduction of new procedures, in particular extended liver resections -which were enabled by increasing surgical expertise and the implementation of multimodal treatment protocols -led to an increasing number of curatively treated patients and significant improvements in long-term results after curative resection. However, numerous patients are not suitable for radical resection because of local tumour growth, intrahepatic metastases, infiltration of main vascular and biliary structures or insufficient remnant liver function. In unresectable tumours, liver transplantation is a curative treatment option for many patients and represents the only chance to achieve long-term survival and cure. Yet, cholangiocarcinomas are not currently a standard indication for liver transplantation, because of the organ shortage and the resulting necessity to allocate available organs to patients with the best prognosis. In recent years, the results of liver transplantation for the different types of cholangiocarcinoma have improved following the application of new treatment protocols. The most promising long-term results were achieved in hilar cholangiocarcinoma by using neoadjuvant radiochemotherapy prior to transplantation. Long-term survival rates were not inferior to those seen in patients receiving a transplantation for benign liver diseases or early-stage hepatocellular carcinoma. The improved long-term outcomes of transplantation for intra-and extrahepatic cholangiocarcinomas have led to a renewed interest for liver transplantation as a treatment for these tumour entities. However, numerous patients with cholangiocarcinomas are not suitable for resection due to local tumour extension or insufficient remnant liver function (see Figure 1) . In particular, patients with an underlying liver disease, such as primary sclerosing cholangitis (PSC), frequently have unresectable cholangiocarcinomas (see Figure 2) . 
transplantation, intrahepatic and hilar cholangiocarcinomas were considered to be ideal indications for liver transplantation. The tumours tend to remain localised within the liver and the liver hilum, respectively, until late in the course of the disease and can often be completely removed by hepatectomy and replacement of a homograft, even if curative resection is not feasible.
1,2 Therefore, liver transplantation represents a curative treatment option in patients with cholangiocarcinomas. However, despite cure obtained in a considerable proportion of patients, the long-term results of the procedure were found to be inferior to those of liver transplantation performed on patients with benign diseases or early-stage hepatocellular carcinoma. [1] [2] [3] [4] In the early 1990s, because of the upcoming organ shortage and the resulting necessity to allocate available organs to patients with the best prospects of success in the long term, cholangiocarcinomas started to be refused as an indication for liver transplantation. 5, 6 However, numerous patients with cholangiocarcinomas are not suitable for resection due to local tumour extension or insufficient remnant liver function (see Figure 1) . In particular, patients with an underlying liver disease, such as primary sclerosing cholangitis (PSC), frequently have unresectable cholangiocarcinomas (see Figure 2 ).
A number of these patients develop cholangiocarcinoma at a younger age, which underlines the need for a curative treatment option in tumours that are not suitable for resection. 7 In this group of patients, liver transplantation remains the only chance of long-term survival and cure. Therefore, liver transplantation remains an important tool in the treatment of patients with cholangiocarcinomas.
In recent years, new treatment approaches have markedly improved patient outcomes. However, liver transplantation used in the treatment of cholangiocarcinomas remains complex and the indication needs to take into account the different biological behaviours, the availability of effective alternative treatment modalities, the current transplant allocation criteria and the individual prognosis.
Hilar Cholangiocarcinoma

The Mayo Clinic Experience
In patients with hilar cholangiocarcinoma, the most promising results of liver transplantation were reported by the Mayo Clinic group in the US, with a protocol that included radiochemotherapy prior to transplantation. In the most recent evaluation of its results, the Mayo Clinic group reported a five-year survival rate of 73 % in 120 patients who finished a treatment protocol of liver transplantation after neoadjuvant radiochemotherapy. 8 In the 
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A five-year survival rate of more than 70 % represents an outstanding success -a success that cannot be achieved through any other treatment modality -and was considered to be completely unrealistic for this type of tumour some years ago.
Gastrointestinal Cancer However, despite the fact that the number of patients who are treated according to the Mayo Clinic protocol is continuously increasing, it is probably still too early to designate neoadjuvant radiochemotherapy and subsequent liver transplantation as the treatment of choice in patients with hilar cholangiocarcinomas. This circumspection is not only due to concerns regarding the validity, but also to concerns regarding the safety of the treatment protocol.
As regards the validity of the protocol, it must be critically noted that the long-term survival rate in the intention-to-treat population is very high. In the first Mayo Clinic study, the five-year survival rate in the intention-to-treat population was 58 %; the figure decreased to 54 % in the most recent study, which is still extremely good. 8, 9 In the first study, the intention-to-treat population comprised 71 patients, of whom only 38 finished the treatment protocol (including liver transplantation); in the most recent study, 184 patients started neoadjuvant radiochemotherapy and 120 finished the treatment protocol (including liver transplantation). 8, 9 The outstanding five-year survival rates even in patients who, for various reasons, were excluded from liver transplantation during the neoadjuvant phase of the treatment, suggest that at least some of these patients may have been originally incorrectly diagnosed with hilar cholangiocarcinoma.
In fact, the Mayo Clinic protocol allows other inclusion criteria than a positive histology, including positive brush cytology, endoscopic biopsy or a carbohydrate antigen (CA) 19-9 level exceeding 100 ng/ml if patients have a morphological visualisation of a malignant stricture without signs of cholangitis. 11 Although, in principle, we accept this as justified and corresponding to general practice, there are doubts regarding the accuracy of the diagnosis.
The restriction concerns also pertain to the selection of patients. In the first Mayo Clinic study, outstanding survival rates were achieved in a highly selected group of younger male patients who had developed hilar cholangiocarcinoma in the context of an underlying PSC. 9 However, the positive effect of the neoadjuvant treatment is not restricted to patients with underlying PSC, but can also be seen in patients without underlying PSC, yet the long-term results of the latter are inferior. In the most recent Mayo Clinic study, in which 120 patients received liver transplantation after neoadjuvant radiochemotherapy, the five-year survival rate was 79 % in patients with underlying PSC, but only 63 % in patients without underlying PSC. Although radiation damages affect lymph vessels, veins and arteries in decreasing frequency, the Mayo Clinic group reported an unusually high rate of vascular complications after liver transplantation. 12 In the most recent Mayo Clinic report, portal vein stenosis with or without thrombosis -mostly detected on a follow-up computed tomography scan performed four months after transplantation -occurred in 20 % of transplanted patients. 8 Furthermore, late stenosis of the artery was observed in 20 % of the patients who had received an arterial anastomosis on the native common hepatic artery. In a previous and more detailed report about vascular complications in liver transplant patients after neoadjuvant radiochemotherapy, the Mayo Clinic group had reported that, altogether, 40 % of 68 studied patients had vascular complications and two of the seven post-operative deaths were due to arterial complications. 13 In another five patients, arterial complications lead to organ failure and re-transplantation. In contrast, portal vein complications did not cause organ failure or death and were successfully treated, percutaneous transhepatic portal angioplasty being the most frequently used intervention. These good results following portal vein angioplasty are in accordance with other reported results in the literature and show that this procedure can be performed safely after neoadjuvant radiochemotherapy. [14] [15] [16] [17] However, it must be noted that, in all patients, multiple interventions were required and that the success over the longer term cannot yet be assessed.
Renewed Interest for Liver Transplantation
The good long-term results of liver transplantation after neoadjuvant radiochemotherapy for the treatment of hilar cholangiocarcinoma prompted a renewed interest for transplantion in this tumour entity.
The new awareness of the potential benefits of liver transplantation in this setting led to new studies, which have confirmed the improvement in long-term outcomes after liver transplantation also without neoadjuvant radiochemotherapy.
A retrospective analysis of 47 hilar cholangiocarcinoma patients who underwent liver transplantation in different German transplant centres showed significantly better post-operative results and long-term survival rates after 1998. 18 The median survival for patients 
Extended Bile Duct Resection
It is not only liver transplantation, but also the extended resection of the whole biliary tree followed by liver transplantation, that currently attracts renewed interest for the treatment of hilar cholangiocarcinoma. New long-term results obtained with 'extended bile duct resection' have recently been published. The method was first described in 1994 and combines a hepatectomy with a Whipple procedure and subsequent liver transplantation, resulting in a complete resection of the biliary tree. 21 First experiences with the method had confirmed its efficacy in patients with hilar cholangiocarcinoma, but had failed to show a significant superiority over other treatment modalities, such as liver transplantation alone or liver resection. 22 Therefore, extended bile duct resection had not been applied to a larger number of patients.
The recent re-evaluation of the method, with five-and 10-year survival rates of 38 %, underlines its therapeutic efficacy. 23 If post-operative deaths are excluded, the five-and 10-year survival rates in patients with nodal-negative tumours even reaches 58 %, although most of these patients suffer from locally advanced hilar cholangiocarcinomas. 
Intrahepatic Cholangiocarcinoma
Intrahepatic cholangiocarcinoma is the second most frequent primary liver cancer. In Europe and North America, for unknown reasons, its incidence has been increasing over the past decades. [24] [25] [26] This rarest entity of cholangiocarcinomas arises from the small peripheral bile ducts of the liver and corresponds histologically to an adenocarcinoma. 27 
Limitations of Curative Resection
Resection represents a curative treatment option and is accompanied by a five-year survival rate of around 30 %. [28] [29] [30] Even in locally advanced and nodal disseminated tumour stages, resection can achieve long-term survival and cure. 28, 30 It is currently considered to be the treatment of choice in patients with intrahepatic cholangiocarcinoma. 31 However, the tumour tends to remain clinically inapparent until late in the course of the disease and is very frequently diagnosed at an advanced stage. As a consequence, in numerous patients, the tumour is considered unresectable due to multiple intrahepatic metastases or infiltration of main vascular and biliary structures. Resection is therefore precluded in these patients due to the high risk of post-operative liver insufficiency.
The need for an effective treatment option in these patients is particularly urgent considering that they frequently develop cholangiocarcinomas at a younger age. 32 The response of cholangiocarcinomas to conventional chemotherapy and radiation is rather poor, thus the prognosis of patients with unresectable intrahepatic cholangiocarcinomas remains poor and long-term survival is seen in rare exceptions only. 31 
US and European Long-term Study Results
Liver transplantation, consisting of complete hepatectomy and subsequent replacement by a liver graft, is in principle a curative treatment option for patients with unresectable intrahepatic cholangiocarcinoma. Therefore, it constitutes an option to offer a curative therapy to a broader share of patients suffering from intrahepatic cholangiocarcinoma. 33 In the early days of transplantation, intrahepatic cholangiocarcinoma, just like hilar cholangiocarcinoma, was a common and generally accepted indication for liver transplantation. 34 Survival rates after liver transplantation were not inferior to those after liver resection and were clearly better than in patients treated palliatively.
The two largest studies of liver transplantation in unresectable intrahepatic cholangiocarcinoma come from the US and Europe. Gastrointestinal Cancer Liver Transplantation for Cholangiocarcinoma
patients represented 3.8 % of all patients with malignant primary liver tumours in Europe. The series showed one-, three-, five-and 10-year survival rates of 59 %, 36 %, 27 % and 20 %, respectively (see Figure 3) . 3 The other large study was an analysis of data from the Cincinnati Transplant Tumour Registry that included 207 patients with unresectable tumours. 35 The survival rates in this series were comparable to those in the ELTR study, with one-, three-and five-year rates of 72 %, 48 % and 23 %, respectively.
In addition, the aforementioned Spanish national survey showed, in 23 patients with intrahepatic cholangiocarcinomas, survival rates of 77 %, 65 %, 42 % and 23 % at one, three, five and 10 years, respectively, with an accumulated survival of 66 months. 19 Furthermore, in a recently published survey from three Scandinavian countries, the five-year survival rate in patients who received liver transplantation for intrahepatic cholangiocarcinoma after 1995 was 38 %. 36 These various studies confirmed that liver transplantation can In the series published by Casavilla et al., the five-year survival rate of patients with solitary, lymph node-negative tumours was 60 %. 40 In the aforementioned Scandinavian survey, the five-year survival rate of cholangiocarcinoma patients at TNM (tumor-node-metastasis) stage 2 or below was 48 %, with TNM stage being a significant prognostic factor. 36 Three patients who received a liver transplant for a suspected hepatocellular carcinoma within the Milan criteria, later diagnosed as intrahepatic cholangiocarcinoma in the post-operative histological examination, were alive and recurrence-free 30 months after transplantation. 37 These results 
